The ADC Cytotoxic Payloads / Warheads market is projected to grow at an annualized rate of 12.4%, till 2030

Roots Analysis has done a detailed report on ADC Cytotoxic Payloads / Warheads: Products and Services Market, 2021-2030” covering key aspects of the industry and identifying key future growth opportunities

 

To order this 130+ page report, which features 50+ figures and 15+ tables, please visit

https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html

 

Key Market Insights

§  Presently, over 40 players are engaged in the development of ADC cytotoxic payloads / warheads. It is worth noting that majority (44%) of the firms engaged in this domain are based in Europe, followed by North America (28%) and Asia Pacific (28%).

§  More than 430 patent applications / granted patents have been filed over the last few years. Majority (80%) of the patents were filed / granted in North America; other key regions with significant intellectual capital include regions of Europe and South Korea

§  Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that, majority of the deals were licensing agreements, representing over 35% of the total number of partnerships signed in the given time period.

§  Close to USD 1,100 million has been invested by both private and public investors, since 2016. Over USD 719 million was raised through venture capital financing, representing over 42% of the overall funding activity in this domain.

§  The market is anticipated to be primarily driven by the demand of auristatins and maytansinoids payloads. It is worth mentioning that ADC cytotoxic payloads / warheads market for microtubule inhibitors is likely to capture nearly 40% of the total market share by 2030.

 

For more information, please visit https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html

 

Table of Contents

 

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Key Questions Answered

1.4. Chapter Outlines

 

2. EXECUTIVE SUMMARY

 

3. INTRODUCTION

3.1. An Overview of Antibody Drug Conjugate (ADC)

3.2. Key Components of ADCs

3.2.1. Cytotoxin Payloads

3.3. Key Steps in ADC Manufacturing

3.3.1. Technical Challenges in ADC Manufacturing

3.3.2. Need Outsourcing

 

3.4. Need for Contract Manufacturing of ADC Payloads / Warheads

3.5. Guidelines for Selecting a Suitable Partner for Cytotoxic Drugs Manufacturing

3.6. Regulatory Considerations for Cytotoxic Drugs Manufacturing

3.7. ADC Payloads / Warheads: Future Outlook

 

4. MARKET OVERVIEW

4.1. ADC Payloads / Warheads: List of Products and Services

4.1.1. Analysis by Type of Payload

4.1.2. Analysis by Microtubule Inhibitors

4.1.3. Analysis by DNA Damaging Agents

4.1.4. Analysis by Topoisomerase Inhibitors

 

4.2. ADC Payloads / Warheads: List of Developers

4.2.1. Analysis by Year of Establishment

4.2.2. Analysis by Location of Headquarters

4.2.3. Analysis by Company Size

 

5. COMPANY PROFILES

5.1. Abzena

5.1.1. Company Overview

5.1.2. Product Portfolio

5.1.3. Recent Developments

5.1.4. Future Outlook

 

5.2. MabPlex

5.2.1. Company Overview

5.2.2. Product Portfolio

5. 2.3. Recent Developments

5. 2.4. Future Outlook

 

5.3. Levena Biopharma

5.3.1. Company Overview

5.3.2. Product Portfolio

5.3.3. Recent Developments

5.3.4. Future Outlook

 

5.4. NJ Bio

5.4.1. Company Overview

5.4.2. Product Portfolio

5.4.3. Recent Developments

5.4.4. Future Outlook

 

5.5. Novasep

5.5.1. Company Overview

5.5.2. Product Portfolio

5.5.3. Recent Developments

5.5.4. Future Outlook

 

5.6. STA Pharmaceutical (a subsidiary of WuXi AppTec)

5.6.1. Company Overview

5.6.2. Product Portfolio

5.6.3. Recent Developments

5.6.4. Future Outlook

 

5.7. Synaffix

5.7.1. Company Overview

5.7.2. Product Portfolio

5.7.3. Recent Developments

5.7.4. Future Outlook

 

6. PARTNERSHIPS AND COLLABORATIONS

6.1. ADC Payloads / Warheads: List of Partnerships and Collaborations

6.1.1. Analysis by Year of Partnership

6.1.2. Analysis by Type of Partnership

6.1.3. Analysis by Year and Type of Partnership

6.1.4. Analysis by Type of Partner and Type of Partnership

6.1.5. Most Active Players: Analysis by Number of Partnerships

6.1.6. Analysis by Intercontinental and Intracontinental Agreements

 

7. RECENT EXPANSIONS

7.1. ADC Payloads / Warheads: List of Recent Expansions

7.2. Cumulative Year-wise Trend

7.3. Analysis by Type of Expansion

7.4. Analysis by Year and Type of Expansion

7.5. Analysis by Location of Facility and Type of Expansion

7.6. Analysis by Location of Facility and Amount Invested

7.7. Industry Players: Analysis by Type of Expansion

7.8. Leading Players: Analysis by Amount Invested

 

8. FUNDING AND INVESTMENT ANALYSIS

8.1. ADC Payloads / Warheads: List of Funding and Investment

8.2. Analysis by Year of Investment

8.3. Analysis by Amount Funded

8.4. Analysis by Type of Funding

8.5. Analysis by Type of Funding and Cumulative Amount Invested

8.6. Geographical Analysis by Total Amount Invested

8.7. Most Active Players: Analysis by Amount Invested

8.8. Most Active Players: Analysis by Amount Raised

 

9. PATENT ANALYSIS

9.1. Analysis Methodology and Key Parameters

9.2. ADC Payloads / Warheads: Patent Analysis

9.2.1. Analysis by Publication Year

9.2.2. Analysis by Type of Patent and Publication Year

9.2.3. Analysis by Type of Patent

9.2.4. Analysis by Geography

9.3.5. Analysis by CPC Symbols

9.2.6. Word Cloud: Emerging Focus Areas

9.2.7. Analysis by Type of Organization

9.2.8. Leading Industry Players: Analysis by Number of Patents

9.2.9. Leading Individual Assignees: Analysis by Number of Patents

 

9.2.10. ADC Payloads / Warheads: Patent Benchmarking Analysis

9.2.10.1. Analysis by Patent Valuation

 

10. DEMAND ANALYSIS

10.1. Chapter Overview

10.2. Key Assumptions and Methodology

10.3. ADC Therapeutics: Overall Annual Demand

10.3.1. ADC Payloads / Warheads: Annual Commercial Demand

10.3.1.1. Analysis by Payload Category

10.3.1.2. Analysis by Type of Payload

 

10.3.2. ADC Payloads / Warheads: Annual Clinical Demand

10.3.2.1. Analysis by Payload Category

10.3.2.2. Analysis by Type of Payload

 

11. CASE STUDY: ADC THERPEUTICS

11.1. Antibody Drug Conjugate: Development Pipeline

11.1.1. Analysis by Phase of Development

11.1.2. Analysis by Therapeutic Area

11.1.3. Analysis by Line of Treatment

11.1.4. Analysis by Dosing Regimen

11.1.5. Analysis by Target Antigen

11.1.6. Analysis by Antibody Isotype

11.1.7. Analysis by Linker Type

11.1.8. Analysis by Payload Category

11.1.9. Analysis by Type of Payload / Warhead

 

12. CASE STUDY: ADC CONTRACT MANUFACTURING ORGANIZATIONs

12.1. ADC Contract Manufacturing: List of Service Providers

12.1.1. Analysis by Type of Service Offered

12.1.2. Analysis by Other Service Offered

12.1.3. Analysis by Scale of Operation

12.2. ADC Contract Manufacturing Service Providers: Information on Service(s) Offered

12.3. ADC Contract Manufacturing Service Providers: Information on Other Service(s) Offered

12.4. ADC Contract Manufacturing Service Providers: Information on Scale of Operation

12.5. ADC Contract Manufacturing Service Providers: Information on Location of Manufacturing Facilities

 

13. MARKET FORECAST

13.1. Key Assumptions and Forecast Methodology

13.2. Global Market Forecast, Till 2035

13.3. Overall ADC Payloads / Warheads Market: Commercial Opportunity

13.3.1. Analysis by Payload Category

13.3.2. Analysis by Type of Payload

 

13.4. Overall ADC Payloads / Warheads Market: Clinical Opportunity

13.4.1. Analysis by Payload Category

13.4.2. Analysis by Type of Payload

 

14. EXECUTIVE INSIGHTS

14.1. Novasep

14.1.1. Company Snapshot

14.1.2. Interview Transcript: Kevin Daley (Market Director)

 

14.2. Synaffix

14.2.1. Company Snapshot

14.2.2. Interview Transcript: Floris Van Delft (Founder and Chief Scientific Officer)

 

15. APPENDIX 1: TABULATED DATA

 

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

 

Contact Details

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com